Loading...
Orgenesis Inc.
ORGS•NASDAQ
Healthcare
Biotechnology
$1.00
$0.86(614.29%)

Financial performance has remained strong, with revenue growing from -$13.60M in Q4 2023 to $347000.00 in Q3 2024. Gross profit continued to perform well, with margins at -69% in the latest quarter. Operating income reached -$8.39M in Q3 2024, holding a steady -2419% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$7.66M. Net income rose to $9.12M, keeping EPS at -$0.19. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan